NCT04703868View on ClinicalTrials.gov

A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

June 1, 2021

Study Completion Date

June 14, 2021

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG

Rabeprazole Sodium 10mg

Part A: 1 tablet administered before the breakfast during 7 days

DRUG

Rabeprazole Sodium 20mg

Part B: 1 tablet administered before the breakfast during 7 days

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors

collaborator

Seoul National University Hospital

OTHER

lead

Yungjin Pharm. Co., Ltd.

INDUSTRY

NCT04703868 - A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter